Unia Europejska - fiński - EMA (European Medicines Agency)

theratechnologies europe limited - ibalizumab - hiv-infektiot - antiviraalit systeemiseen käyttöön - trogarzo, yhdessä muiden antiretroviraalisten(s), on tarkoitettu hoitoon aikuisille tartunnan kanssa useita resistenttejä hiv-1-infektio, joille se ei muuten ole mahdollista rakentaa tukahduttava antiviraalinen hoito.

Unia Europejska - fiński - EMA (European Medicines Agency)

accord healthcare s.l.u. - tigesykliini - soft tissue infections; intraabdominal infections; bacterial infections; skin diseases, infectious - systeemiset bakteerilääkkeet, - tygecycline accord on tarkoitettu aikuisten ja lasten iästä alkaen kahdeksan vuotta hoitoon seuraavien infektioiden hoitoon (ks. kohdat 4. 4 ja 5. 1):komplisoituneet ihon ja pehmytkudoksen infektioiden (cssti), pois lukien diabeettinen jalka infektioita (ks. kohta 4. 4)komplisoituneet intra-abdominaaliset infektiot (ciai)tygecycline accord tulisi käyttää vain tilanteissa, joissa muita vaihtoehtoisia antibiootteja eivät sovi (ks. kohdat 4. 4, 4. 8 ja 5. on otettava huomioon viralliset ohjeet antibioottien tarkoituksenmukaisesta käytöstä.

Unia Europejska - fiński - EMA (European Medicines Agency)

amivas ireland ltd - artesunate - malaria - antiprototsooisia - artesunate amivas is indicated for the initial treatment of severe malaria in adults and children. on otettava huomioon viralliset ohjeet antibioottien asianmukaisesta käytöstä malarian aineet.

Unia Europejska - fiński - EMA (European Medicines Agency)

h. lundbeck a/s - eptinezumab - migreenihäiriöt - kipulääkkeet - vyepti is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.

Unia Europejska - fiński - EMA (European Medicines Agency)

sanofi b.v. - olipudase alfa - acid sphingomyelinase deficiency (asmd) type a/b or type b - muut ruuansulatuselimistön sairauksien ja aineenvaihduntasairauksien lääkkeet, - xenpozyme is indicated as an enzyme replacement therapy for the treatment of non-central nervous system (cns) manifestations of acid sphingomyelinase deficiency (asmd) in paediatric and adult patients with type a/b or type b.

Unia Europejska - fiński - EMA (European Medicines Agency)

astrazeneca ab - tezepelumab - astma - obstruktiivisten hengitystiesairauksien lääkkeet, - tezspire is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.

Unia Europejska - fiński - EMA (European Medicines Agency)

gilead sciences ireland unlimited company - lenacapavir sodium - hiv-infektiot - antiviraalit systeemiseen käyttöön - sunlenca injection, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant hiv 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen (see sections 4. 2 ja 5. sunlenca tablet, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant hiv 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen, for oral loading prior to administration of long-acting lenacapavir injection (see sections 4. 2 ja 5.

Unia Europejska - fiński - EMA (European Medicines Agency)

swedish orphan biovitrum ab - loncastuximab tesirine - lymphoma, large b-cell, diffuse; lymphoma, b-cell - antineoplastiset aineet - zynlonta as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl), after two or more lines of systemic therapy.

Unia Europejska - fiński - EMA (European Medicines Agency)

eli lilly nederland b.v. - mirikizumab - paksusuolitulehdus, haavaumia - immunosuppressantit - omvoh is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.

Unia Europejska - fiński - EMA (European Medicines Agency)

bayer ag - riociguat - hypertensio, keuhkokuume - keuhkoverenpainetaudin verenpainelääkkeet - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. teho on osoitettu in pah väestöön, mukaan lukien etiologia idiopaattinen tai periytyviä pah-yhdisteiden tai pah-yhdisteiden liittyy sidekudoksen sairaus. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.